| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
66,921,000 |
| Market
Cap: |
2.83(B) |
| Last
Volume: |
1,212,774 |
Avg
Vol: |
1,000,279 |
| 52
Week Range: |
$38.26 - $93.23 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile QuidelOrtho is engaged in the development, manufacturing and marketing of diagnostic testing solutions. Co. provides diagnostic testing solutions under various brand names, including, among others, the following: Quidel®, QuickVue®, QuickVue+®, Sofia®, Triage®, Solana®, Virena®, MicroVue™, Lyra®, FreshCells™, D3®, FastPoint®, ReadyCells®, Super E-Mix™, InflammaDry®, AdenoPlus®, ELVIRA®, ELVIS® and Thyretain®. Co.'s diagnostic testing solutions are separated into its four product categories: rapid immunoassay, cardiometabolic immunoassay, molecular diagnostic solutions and specialized diagnostic solutions.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bryant Douglas C |
President & CEO |
• • – |
2021-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
32,538 |
500,089 |
|
- |
|
| Bujarski Robert Joseph |
Chief Operating Officer |
• – – |
2021-02-18 |
4 |
D |
$210.10 |
$857,418 |
D/D |
(4,081) |
25,167 |
|
- |
|
| Bujarski Robert Joseph |
Chief Operating Officer |
• – – |
2021-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
8,229 |
26,964 |
|
- |
|
| Kroll Werner |
SVP, R&D |
• – – |
2021-02-18 |
4 |
D |
$210.10 |
$920,658 |
D/D |
(4,382) |
18,237 |
|
- |
|
| Kroll Werner |
SVP, R&D |
• – – |
2021-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
8,531 |
20,253 |
|
- |
|
| Ranalli Tamara A. |
SVP, Molecular Bus. Unit |
• – – |
2021-02-18 |
4 |
D |
$210.10 |
$211,361 |
D/D |
(1,006) |
12,063 |
|
- |
|
| Ranalli Tamara A. |
SVP, Molecular Bus. Unit |
• – – |
2021-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
3,237 |
12,648 |
|
- |
|
| Russell Edward Keith |
SVP, Business Development |
• – – |
2021-02-18 |
4 |
D |
$210.10 |
$857,418 |
D/D |
(4,081) |
26,126 |
|
- |
|
| Russell Edward Keith |
SVP, Business Development |
• – – |
2021-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
8,229 |
27,923 |
|
- |
|
| Bryant Douglas C |
President & CEO |
• • – |
2021-02-17 |
4 |
D |
$217.79 |
$1,266,667 |
D/D |
(5,816) |
474,402 |
|
- |
|
| Bryant Douglas C |
President & CEO |
• • – |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
12,171 |
475,795 |
|
- |
|
| Bujarski Robert Joseph |
Chief Operating Officer |
• – – |
2021-02-17 |
4 |
D |
$217.79 |
$493,512 |
D/D |
(2,266) |
21,019 |
|
- |
|
| Bujarski Robert Joseph |
Chief Operating Officer |
• – – |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,740 |
21,562 |
|
- |
|
| Kroll Werner |
SVP, R&D |
• – – |
2021-02-17 |
4 |
D |
$217.79 |
$493,730 |
D/D |
(2,267) |
14,088 |
|
- |
|
| Kroll Werner |
SVP, R&D |
• – – |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,574 |
14,630 |
|
- |
|
| Russell Edward Keith |
SVP, Business Development |
• – – |
2021-02-15 |
4 |
D |
$227.97 |
$791,056 |
D/D |
(3,470) |
21,978 |
|
- |
|
| Russell Edward Keith |
SVP, Business Development |
• – – |
2021-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
7,172 |
25,448 |
|
- |
|
| Ranalli Tamara A. |
SVP, Molecular Bus. Unit |
• – – |
2021-02-15 |
4 |
D |
$227.97 |
$37,615 |
D/D |
(165) |
9,832 |
|
- |
|
| Ranalli Tamara A. |
SVP, Molecular Bus. Unit |
• – – |
2021-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
675 |
9,997 |
|
- |
|
| Kroll Werner |
SVP, R&D |
• – – |
2021-02-15 |
4 |
D |
$227.97 |
$839,614 |
D/D |
(3,683) |
11,781 |
|
- |
|
| Kroll Werner |
SVP, R&D |
• – – |
2021-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
7,172 |
15,464 |
|
- |
|
| Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
• – – |
2021-02-15 |
4 |
D |
$227.97 |
$53,345 |
D/D |
(234) |
5,379 |
|
- |
|
| Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
• – – |
2021-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
675 |
5,613 |
|
- |
|
| Steward Randall J |
Chief Financial Officer |
• – – |
2021-02-15 |
4 |
D |
$227.97 |
$858,535 |
D/D |
(3,766) |
10,315 |
|
- |
|
| Steward Randall J |
Chief Financial Officer |
• – – |
2021-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
7,594 |
14,081 |
|
- |
|
799 Records found
|
|
Page 6 of 32 |
|
|
2.54 (6.4%) 
